Antilymphocyte antibodies (ALA) occur spontaneously as autoantibodies in many patients with rheumatic diseases and are most frequently found in patients with systemic lupus erythematosus (SLE).`-6
They may also appear after alloimmunisation by multiple pregnancies, multiple blood transfusions, and organ transplantation and with certain infections.3À lthough certain properties of these antibodies have been established, their pathogenetic significance remains unclear. , ALA are usually detected by complement lysis in a microcytotoxicity test,3 indirect immunofluorescence, -" inhibition of certain immune functions such as response to allogeneic stimulation and phytohaemmagglutinin,'3 14 inhibition of generation of suppressor cell activity by concanavalin A,"`7 and by binding of '25I-protein A."6 The microcytotoxicity test depends on antibody binding at low temperature followed by complement activation to damage the target cell. Most of these antibodies are IgM with increased reactivity at cold temperatures. The antibodies which interfere with lymphocyte functions are found in both the IgG and IgM classes and react optimally at 37°C. Immunofluorescent studies have also demonstrated both IgG and IgM ALA. A higher incidence of warm reactive IgG ALA was found by preventing capping and shedding of antibody, as previously described. 6 ''51-labelled protein A detects ALA in patients with active SLE by combining to the Fc portion of lymphocyte-bound IgG." 8 One potential mechanism for lymphocyte damage produced by ALA which has not been extensively studied is antibody-dependent cellular cytotoxicity (ADCC). ADCC is a cytolytic process (Fig. 2 ).
An effector cell negative control was included in all experiments. To Table 1 ). The positive sera were obtained from 5 female LE patients who had severe multisystem disease and were being treated with prednisolone and/or cytotoxic therapy. As indicated in Table 1 , sera 2, 4, and 5 were positive with PBL from all donors tested, and sera 1 and 3 induced ADCC of PBL from 3 of 6 and 3 of 4 donors respectively. The mean (+ SD) ADCC-CI for all SLE sera was 12 8% + 1 9%. The mean ADCC-CI for positive sera was 57 % ± 7 6. For the remaining negative sera the mean CI was 6-3 % + 0-8, which is similar to the CI of 5*5% obtained with NHS, the negative serum control. Four of the positive LE sera and the RaALA were separated into IgG and IgM fractions. 
